Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NX-5948 in R/R CLL/SLL
NCT07221500Phase 2Recruiting
- Sponsor
- Nurix Therapeutics
- Start
- Oct 2025
- Primary completion
- Jan 2028
- Countries
- 5
01
Overview
A Phase 2 trial of bexobrutideg in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Nurix Therapeutics. Started Oct 2025; status: recruiting.
02
Drugs
bexobrutideg
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07221500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221500.